Inhibitors of bcr-abl... Breaking new ground again

The report of a new class of potent and highly selective inhibitors of Bcr-abl highlights the potential for a truly leukemia-specific drug with no expected off-target activity. GNF-2, as a

representative compound of this class, may have inspired the identification of a region of Bcr-abl that is amenable to drug design, just as imatinib did almost a decade ago. Access through

your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12

print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be

subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support

REFERENCES * Druker, B.J. et al. _Nat. Med._ 2, 561–566 (1996). Article  CAS  Google Scholar  * Adrian, F.J. et al. _Nat. Chem. Biol._ 2, 95–102 (2006). Article  CAS  Google Scholar  *

Schindler, T. et al. _Science_ 289, 1938–1942 (2000). Article  CAS  Google Scholar  * Goldman, J.M. & Melo, J.V. _N. Engl. J. Med._ 349, 1451–1464 (2003). Article  CAS  Google Scholar  *

Branford, S. et al. _Blood_ 102, 276–283 (2003). Article  CAS  Google Scholar  * Azam, M., Latek, R.R. & Daley, G.Q. _Cell_ 112, 831–843 (2003). Article  CAS  Google Scholar  * Carter,

T.A. et al. _Proc. Natl. Acad. Sci. USA_ 102, 11011–11016 (2005). Article  CAS  Google Scholar  * Nagar, B. et al. _Cell_ 112, 859–871 (2003). Article  CAS  Google Scholar  * Posner, B.A.

_Curr. Opin. Drug Discov._ 8, 487–494 (2005). CAS  Google Scholar  Download references ACKNOWLEDGEMENTS The authors would like to thank Dick Leopold for his thoughtful review of the

manuscript and Chris Faehnjle for his assistance in the preparation of the figure. AUTHOR INFORMATION Author notes * Jeffrey F. Ohren and Judith S. Leopold: Jeffrey F. Ohren is in Chemical

Technologies and Judith S. Leopold is in Mechanistic and Target Biology AUTHORS AND AFFILIATIONS * Ann Arbor Laboratories, Pfizer Global Research and Development, Ann Arbor, 48105, Michigan,

USA Jeffrey F Ohren & Judith S Sebolt-Leopold Authors * Jeffrey F Ohren View author publications You can also search for this author inPubMed Google Scholar * Judith S Sebolt-Leopold

View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Ohren, J.,

Sebolt-Leopold, J. Inhibitors of Bcr-abl... breaking new ground again. _Nat Chem Biol_ 2, 63–64 (2006). https://doi.org/10.1038/nchembio0206-63 Download citation * Issue Date: February 2006

* DOI: https://doi.org/10.1038/nchembio0206-63 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is

not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative